Genscript Biotech (1548) Aktievy
Genscript Biotech Corporation är ett investmentbolag som tillverkar och säljer produkter och tjänster för biovetenskaplig forskning i USA, Europa, Kina, Europa, Asien och Stillahavsområdet samt internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 6/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för 1548 från våra riskkontroller.
1548 Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Genscript Biotech Corporation Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | HK$12.97 |
| 52 veckors högsta | HK$19.40 |
| 52 veckors lägsta | HK$10.36 |
| Beta | 0.96 |
| 1 månads förändring | -6.35% |
| 3 månaders förändring | 5.36% |
| 1 års förändring | 5.45% |
| 3 års förändring | -29.66% |
| 5 års förändring | -52.58% |
| Förändring sedan börsintroduktionen | 882.58% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • May 12
1548: European mRNA Expansion Will Support Future Upside Potential
Analysts have kept their HK$17.67 price target for Genscript Biotech broadly unchanged, with only slight tweaks to the discount rate and future P/E assumptions shaping this latest narrative update. What's in the News GenScript plans to put amendments to its fourth amended and restated memorandum and articles of association to a shareholder vote at the AGM on June 5, 2026, and proposes adopting a fifth amended and restated version of these governing documents (Key Developments).Uppdatering av berättelse • Apr 24
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).Uppdatering av berättelse • Apr 10
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).
Ny berättelse • Mar 31
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?Recent updates
Uppdatering av berättelse • May 12
1548: European mRNA Expansion Will Support Future Upside Potential
Analysts have kept their HK$17.67 price target for Genscript Biotech broadly unchanged, with only slight tweaks to the discount rate and future P/E assumptions shaping this latest narrative update. What's in the News GenScript plans to put amendments to its fourth amended and restated memorandum and articles of association to a shareholder vote at the AGM on June 5, 2026, and proposes adopting a fifth amended and restated version of these governing documents (Key Developments).Uppdatering av berättelse • Apr 24
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).Uppdatering av berättelse • Apr 10
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).Ny berättelse • Mar 31
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Mar 25
1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).Uppdatering av berättelse • Mar 10
1548: Higher Future P/E Assumptions Will Support Ongoing Upside Potential
Analysts have adjusted their HK$ price target for Genscript Biotech to reflect updated views on discount rate, long term profit margins and a higher assumed future P/E multiple. This has resulted in a modest recalibration of fair value rather than a wholesale shift in the investment case.Uppdatering av berättelse • Feb 23
1548: Slightly Lower Future P/E Will Still Support Attractive Upside Potential
Analysts have trimmed their price target on Genscript Biotech to reflect a slightly lower assumed future P/E multiple, while keeping fair value broadly unchanged at about HK$22.12. They cite fine tuning of discount rate and margin assumptions rather than any major shift in the core outlook.Uppdatering av berättelse • Feb 09
1548: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have trimmed their fair value estimate for Genscript Biotech from $23.52 to $22.12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Genscript Biotech held an Analyst/Investor Day, giving the market a closer look at its business, capital plans, and the assumptions that feed into analyst models (Key Developments).Analysartikel • Nov 03
Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
With a median price-to-sales (or "P/S") ratio of close to 5.5x in the Life Sciences industry in Hong Kong, you could be...Analysartikel • Oct 10
Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Key Insights Genscript Biotech's estimated fair value is HK$30.13 based on 2 Stage Free Cash Flow to Equity Genscript...Analysartikel • Sep 18
We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
The market for Genscript Biotech Corporation's ( HKG:1548 ) shares didn't move much after it posted weak earnings...Analysartikel • Sep 08
Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Uppdatering av berättelse • Aug 21
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Despite a sharp decline in consensus revenue growth forecasts and a substantial jump in future P/E, analysts have raised Genscript Biotech's fair value estimate from HK$21.61 to HK$23.01. What's in the News GenScript Biotech launched a new global brand platform, "Scripting Possibilities," alongside a refreshed visual identity and expanded marketing initiatives to drive growth and strengthen global brand presence.Analysartikel • Jul 29
Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues
Genscript Biotech Corporation ( HKG:1548 ) shares have continued their recent momentum with a 28% gain in the last...Analysartikel • Jul 24
At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?
Genscript Biotech Corporation ( HKG:1548 ), might not be a large cap stock, but it saw a significant share price rise...Ny berättelse • Jul 17
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Analysartikel • May 14
Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Apr 07
Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Genscript Biotech Corporation ( HKG:1548 ) shares have retraced a considerable 27% in the last month, reversing a fair...Analysartikel • Feb 12
Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump
Genscript Biotech Corporation ( HKG:1548 ) shares have had a really impressive month, gaining 27% after a shaky period...Analysartikel • Jan 20
Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Genscript Biotech is HK$19.29 based on 2 Stage Free Cash Flow to Equity...Analysartikel • Nov 19
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
It's not a stretch to say that Genscript Biotech Corporation's ( HKG:1548 ) price-to-sales (or "P/S") ratio of 2.9x...Analysartikel • Oct 01
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Sep 16
What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Genscript Biotech Corporation ( HKG:1548 ), might not be a large cap stock, but it received a lot of attention from a...Analysartikel • Aug 02
After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Genscript Biotech Corporation ( HKG:1548 ) shares have had a really impressive month, gaining 44% after a shaky period...Analysartikel • Jun 05
Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Unfortunately for some shareholders, the Genscript Biotech Corporation ( HKG:1548 ) share price has dived 28% in the...Analysartikel • May 10
A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Key Insights The projected fair value for Genscript Biotech is HK$14.11 based on 2 Stage Free Cash Flow to Equity With...Analysartikel • Apr 13
Is Genscript Biotech (HKG:1548) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysartikel • Mar 13
Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Genscript Biotech Corporation ( HKG:1548 ) shareholders are no doubt pleased to see that the share price has bounced...Analysartikel • Jan 26
Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Genscript Biotech Corporation ( HKG:1548 ) shareholders that were waiting for something to happen have been dealt a...Analysartikel • Nov 21
Is Genscript Biotech (HKG:1548) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Aug 22
Is Genscript Biotech (HKG:1548) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Apr 04
Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
The analysts covering Genscript Biotech Corporation ( HKG:1548 ) delivered a dose of negativity to shareholders today...Analysartikel • Apr 03
Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
It's been a mediocre week for Genscript Biotech Corporation ( HKG:1548 ) shareholders, with the stock dropping 10% to...Analysartikel • Apr 02
Is Genscript Biotech (HKG:1548) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Aktieägarnas avkastning
| 1548 | HK Life Sciences | HK Marknad | |
|---|---|---|---|
| 7D | -7.8% | -1.9% | -1.5% |
| 1Y | 5.4% | 38.8% | 11.3% |
Avkastning vs industri: 1548 presterade sämre än Hong Kong Life Sciences branschen som gav 38.8 % under det senaste året.
Avkastning vs Marknaden: 1548 presterade sämre än Hong Kong marknaden som gav 11.3 % under det senaste året.
Prisvolatilitet
| 1548 volatility | |
|---|---|
| 1548 Average Weekly Movement | 6.8% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.8% |
| 10% least volatile stocks in HK Market | 3.5% |
Stabil aktiekurs: 1548 har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Hong Kong.
Volatilitet över tid: 1548 s veckovolatilitet ( 7% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2002 | 6,165 | Sherry Shao | www.genscript.com |
Genscript Biotech Corporation är ett investmentbolag som tillverkar och säljer produkter och tjänster för biovetenskaplig forskning i USA, Europa, Kina, Europa, Asien och Stillahavsområdet samt internationellt. Verksamheten bedrivs genom tre segment: Life Science Services and Products; Biologics Development Services; och Industrial Synthetic Biology Products. Segmentet Life Science Services and Products tillhandahåller produkter och tjänster inom olika kategorier, bland annat gensyntes, oligonukleotidsyntes, peptidsyntes, protein engineering, antikroppsutveckling samt utrustning och förbrukningsvaror för biovetenskap, till exempel verktyg för molekylär diagnostik och material för genomredigering för biologistudier, läkemedelsforskning, sjukdomsdiagnostik och vaccin, jordbruk, miljöstudier och livsmedelsindustrin.
Genscript Biotech Corporation Sammanfattning av grunderna
| 1548 grundläggande statistik | |
|---|---|
| Börsvärde | HK$28.38b |
| Vinst(TTM) | -HK$4.18b |
| Intäkter(TTM) | HK$7.52b |
3.8x
P/S-förhållande-6.8x
P/E-förhållandeÄr 1548 övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| 1548 resultaträkning (TTM) | |
|---|---|
| Intäkter | US$959.53m |
| Kostnad för intäkter | US$406.32m |
| Bruttovinst | US$553.20m |
| Övriga kostnader | US$1.09b |
| Intäkter | -US$532.83m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.24 |
| Bruttomarginal | 57.65% |
| Nettovinstmarginal | -55.53% |
| Skuld/egenkapitalförhållande | 7.1% |
Hur har 1548 utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/24 16:17 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Genscript Biotech Corporation bevakas av 12 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wai Chak Yuen | Daiwa Securities Co. Ltd. |